Hold Sun Pharmaceuticals; target of Rs 480: Edelweiss

Edelweiss' research report on Sun Pharmaceuticals

Sun Pharma (SUNP) is the only company among peers to have made significant investments (~USD1.5bn) in specialty US business. The company’s ‘string of pearls’ strategy of sourcing external innovation by acquiring assets rather than companies, involves low risk but also offers low returns. Our deep-dive analysis of SUNP’s specialty portfolio suggests – 1) significant challenges in the build-up stage, 2) cash guzzle over next three-four years, and 3) potential over-estimation by the street. Specialty pipeline likely to add USD300mn revenue in next 5 years as decline in Absorica and Levulan-Kerastick offset key assets – Ilumya (tildrakizumab) and Seciera.

Outlook

Though, Sun’s strategy of moving into specialty is a prudent step, shifting from generics will have a steep learning curve. We maintain ‘HOLD’ with a revised target price of INR480 (INR550 earlier).

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More